BRIEF published on 10/01/2024 at 00:45, 1 year 2 months ago Valerio Therapeutics Reports Half-Year 2024 Financial Results and Strategic Updates Financial Results Emglev Acquisition VIO-01 Clinical Trial PlatON™ Platform Therapeutic Innovations
PRESS RELEASE published on 10/01/2024 at 00:40, 1 year 2 months ago Inside Information: News release on accounts, results Valerio Therapeutics reports its half-year 2024 financial results and updates on its activities, including the acquisition of Emglev Therapeutics and progress on the VIO-01 trial Acquisition Financial Results Valerio Therapeutics VIO-01 Trial Emglev Therapeutics
PRESS RELEASE published on 09/30/2024 at 22:40, 1 year 2 months ago Half yearly financial reports and audit reports/limited reviews / Half yearly financial report
BRIEF published on 08/05/2024 at 19:23, 1 year 3 months ago Half-yearly review of the liquidity contract with Kepler Cheuvreux Liquidity Contract Transactions Kepler Cheuvreux AMF Valerio Therapeutics
PRESS RELEASE published on 08/05/2024 at 19:18, 1 year 3 months ago Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract Valerio Therapeutics releases half-year liquidity contract statement revealing shares and trading volumes Liquidity Contract Shares AMF Decision Valerio Therapeutics Trading Volumes
BRIEF published on 06/05/2024 at 07:05, 1 year 5 months ago Minutes of the general meeting of Valerio Therapeutics Biotechnology Voting Results General Meeting Resolutions Valerio Therapeutics
PRESS RELEASE published on 06/05/2024 at 07:00, 1 year 5 months ago Inside Information / Other news releases Valerio Therapeutics reports successful Combined General Meeting with 48.1% quorum, adopting all resolutions. Consolidated vote results and meeting minutes to be available on the Company's website Euronext Growth Paris Biotechnology General Meeting Valerio Therapeutics DDR Drugs
BRIEF published on 05/22/2024 at 20:51, 1 year 6 months ago Valerio Therapeutics Advances VIO-01 Clinical Trial with Positive Results Drug Development Solid Tumors Clinical Trial Valerio Therapeutics VIO-01
PRESS RELEASE published on 05/22/2024 at 20:46, 1 year 6 months ago Inside Information / Other news releases Valerio Therapeutics completes dosing for first cohort of subjects in Phase 1/2 VIO-01 trial for solid tumors, showing encouraging tolerability. Phase 1b aims to determine recommended dose in selected solid tumors Solid Tumors Valerio Therapeutics VIO-01 Trial Phase 1/2 DNA Damage Response
BRIEF published on 04/30/2024 at 23:19, 1 year 7 months ago Valerio Therapeutics Reports 2023 Fiscal Year Results and Clinical Updates Biotechnology Clinical Trials Financial Results 2023 Valerio Therapeutics VIO-01
Published on 12/05/2025 at 02:35, 3 hours 37 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 12 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 7 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 12 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 2 hours 42 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 21 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 47 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 57 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 2 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 12 hours 12 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 27 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 28 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 11 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago Declaration of voting rights at the end of November 2025
